Abstract
Chronic kidney disease (CKD) poses a significant health risk in contemporary society. Current CKDtreatments primarily involve renin-angiotensin-aldosterone system inhibitors and mineralocorticoid receptorantagonists, albeit associated with hyperkalemia risks. A novel selective mineralocorticoid receptor antagonist,finerenone, offers a promising, safer alternative for CKD therapy. This review comprehensively assesses the role and efficacy of finerenone in CKD treatment byanalyzing clinical and animal studies. Emerging evidence consistently supports finerenone's ability to effectivelyslow the progression of CKD. By targeting the mineralocorticoid receptor, finerenone not only mitigates renaldamage but also exhibits a favorable safety profile, minimizing hyperkalemia concerns. Finerenone emerges as a valuable addition to CKD therapy, demonstrating potential benefits indelaying CKD progression while minimizing side effects. Nevertheless, further clinical trials are necessary toprovide a comprehensive understanding of its safety and efficacy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
